Background: Increasing copayments for higher-priced prescription medications has been
suggested as a means to help finance drug coverage for elderly patients, but evaluations of …

Background In January 1997, reference pricing for angiotensin-converting–enzyme (ACE)
inhibitors for patients 65 years of age or older was introduced in British Columbia, Canada …

Background: Reference-based pricing is a cost-containment policy applied to prescription
drugs that are in the same class and deemed to be therapeutically equivalent. Recent …

Background: Reference drug pricing (RP) is a cost-sharing strategy commonly used to
control drug expenditures. Under RP, a benefit plan fully reimburses medications that are …

OBJECTIVES: Impact assessment of drug benefits policies is a growing field of research that
is increasingly relevant to healthcare planning for older people. Some cost‐containment …

Reference pricing (RP) limits drug plan reimbursement of interchangeable medicines to a
reference price, which is typically equal to the price of the lowest‐cost interchangeable drug; …

Background: Current hypertension guidelines differ in their recommendations for first-line
antihypertensive therapy. Objective: To evaluate the cost effectiveness of ACE inhibitor …

The US Department of Defense recently assembled electronic records of outpatient
prescriptions dispensed through the Uniformed Services Prescription Database Project …

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors and angiotens in receptor
blockers (ARBs) are widely prescribed for the treatment of hypertension and heart failure, as …

Objective: To compare the cost effectiveness of the angiotensin II receptor blockers (ARBs)
olmesartan medoxomil, losartan, valsartan and irbesartan for the treatment of hypertension …